Role of cytochrome P450 2C8 and 2J2 genotypes in calcineurin inhibitor-induced chronic kidney disease.
about
Analysis of epoxyeicosatrienoic acids by chiral liquid chromatography/electron capture atmospheric pressure chemical ionization mass spectrometry using [13C]-analog internal standards.PharmGKB summary: cyclosporine and tacrolimus pathwaysCytochrome P450 2J2: distribution, function, regulation, genetic polymorphisms and clinical significance.Cerivastatin in vitro metabolism by CYP2C8 variants found in patients experiencing rhabdomyolysisCharacterization of the metabolism of fenretinide by human liver microsomes, cytochrome P450 enzymes and UDP-glucuronosyltransferases.Drug metabolism by CYP2C8.3 is determined by substrate dependent interactions with cytochrome P450 reductase and cytochrome b5.Genetic markers in the EET metabolic pathway are associated with outcomes in patients with aneurysmal subarachnoid hemorrhageGenetic and clinical determinants of early, acute calcineurin inhibitor-related nephrotoxicity: results from a kidney transplant consortium.The 6R's of drug induced nephrotoxicityMetabolism of Anandamide by Human Cytochrome P450 2J2 in the Reconstituted System and Human Intestinal Microsomes.Exploring genetic and non-genetic risk factors for delayed graft function, acute and subclinical rejection in renal transplant recipients.Pharmacogenetic considerations for optimizing tacrolimus dosing in liver and kidney transplant patientsEpoxyeicosatrienoic acids: formation, metabolism and potential role in tissue physiology and pathophysiology.Integrating genomics into biobehavioral research: a transplantation exemplar.Early use of renal-sparing agents in liver transplantation: a closer look.PharmGKB summary: very important pharmacogene information for cytochrome P450, family 2, subfamily C, polypeptide 8.The role of pharmacogenetics in the disposition of and response to tacrolimus in solid organ transplantation.Targeted chiral analysis of bioactive arachidonic Acid metabolites using liquid-chromatography-mass spectrometry.Pharmacogenetic aspects of the use of tacrolimus in renal transplantation: recent developments and ethnic considerations.Influence of ABCC2, CYP2C8, and CYP2J2 Polymorphisms on Tacrolimus and Mycophenolate Sodium-Based Treatment in Brazilian Kidney Transplant Recipients.Effect of Cytochrome P450 Metabolites of Arachidonic Acid in Nephrology.PharmGKB summary: cytochrome P450, family 2, subfamily J, polypeptide 2: CYP2J2.Long-Term Impact of Cyclosporin Reduction with MMF Treatment in Chronic Allograft Dysfunction: REFERENECE Study 3-Year Follow UpPolymorphisms in cytochromes P450 2C8 and 3A5 are associated with paclitaxel neurotoxicity.SNPs and taxane toxicity in breast cancer patients.Prediction of olanzapine exposure in individual patients using physiologically based pharmacokinetic modelling and simulation.Heme Modification Contributes to the Mechanism-Based Inactivation of Human Cytochrome P450 2J2 by Two Terminal Acetylenic Compounds.CYP2J2 - regulation, function and polymorphism.
P2860
Q33448255-5510C23C-9A32-4839-BEEA-4184B8C26940Q33989902-5D761A5C-E53F-4FE6-B69F-C9E24D9F5838Q34358307-A8A32D6D-9E41-42F1-BA5C-CB3F2E49350EQ34360732-7BF2C81B-AB9D-4718-8379-EBA4F60B10F7Q34588717-6F81BC9D-85E0-4118-B0F9-B9F2DE2D4627Q35175018-82BA083B-D985-4B03-982E-FD0B8250EA34Q35591243-FC196E61-DCAC-453B-AD07-AE17236D4898Q35823308-A07DAD4D-33D2-401F-B8F7-07D7711B0291Q36333140-893141F9-F42E-49BC-97FA-8B552D96AC71Q36947747-E7188FE9-4283-4F35-A12F-0AAE16838A60Q37030707-EF9B0502-B6F6-42E0-BDF2-44DE347799B0Q37439873-D718E320-D257-47A9-81F6-6E47656B032BQ37510865-93072E6C-0965-4285-94C6-8719B316948BQ37665269-32F52EA0-FFEB-4E9E-A333-18EFDC26A301Q38108593-4BB51E8C-962E-4E51-A37E-447A8909F311Q38130410-F0288C88-9A38-4751-BA65-69F656DACAB0Q38163945-D28F84D3-B012-4E6B-977E-AB51E5AC0D2FQ38222606-5CFE4ECD-1617-4E9C-A219-AB8D79A5CCCDQ38787174-9AD37C0D-37ED-4A34-B194-EC43783368E2Q38896041-4F85645A-CA82-4969-9FB5-8672EBB4BC45Q39431317-28AAB5A8-5967-40B2-9595-A977204C8F1CQ41764712-4F37A79B-843D-4F30-BCA0-5BC63247E5DAQ42612170-50688740-E467-44FA-8A76-4EE874C24CE8Q43496569-701E6995-883F-4A4A-8064-36F3BC90D352Q46800256-3098DC26-AA23-4C8E-9C4A-614210F3EC1CQ47384439-DE1C3967-A7CD-4274-B3AD-9D153479EDF6Q50534856-3C33F0F3-7337-4D43-9F5A-557BF90DC290Q51709663-7C3BE885-DA79-4D60-9BE5-4CD4DE1B4B6C
P2860
Role of cytochrome P450 2C8 and 2J2 genotypes in calcineurin inhibitor-induced chronic kidney disease.
description
2008 nî lūn-bûn
@nan
2008年の論文
@ja
2008年学术文章
@wuu
2008年学术文章
@zh-cn
2008年学术文章
@zh-hans
2008年学术文章
@zh-my
2008年学术文章
@zh-sg
2008年學術文章
@yue
2008年學術文章
@zh
2008年學術文章
@zh-hant
name
Role of cytochrome P450 2C8 an ...... nduced chronic kidney disease.
@en
Role of cytochrome P450 2C8 an ...... nduced chronic kidney disease.
@nl
type
label
Role of cytochrome P450 2C8 an ...... nduced chronic kidney disease.
@en
Role of cytochrome P450 2C8 an ...... nduced chronic kidney disease.
@nl
prefLabel
Role of cytochrome P450 2C8 an ...... nduced chronic kidney disease.
@en
Role of cytochrome P450 2C8 an ...... nduced chronic kidney disease.
@nl
P2093
P2860
P1476
Role of cytochrome P450 2C8 an ...... nduced chronic kidney disease.
@en
P2093
Connie L Davis
David K Blough
Federico M Farin
Helen E Smith
James D Perkins
Kenneth E Thummel
Mary F Hebert
Patricia L Stapleton
Rheem A Totah
P2860
P304
P356
10.1097/FPC.0B013E32830E1E16
P577
2008-11-01T00:00:00Z